Disulfiram Should NOT Be Used in Chronic Liver Disease with Early Fibrosis
Disulfiram is contraindicated in patients with chronic liver disease, including those with early fibrosis, and should be avoided in favor of safer alternatives like acamprosate or baclofen. 1, 2
Guideline-Based Contraindication
The American Association for the Study of Liver Diseases (AASLD) 2019 practice guidance explicitly states that "Disulfiram is not included on this list because it is not recommended for use in patients with ALD" when discussing relapse prevention medications 1. This recommendation applies to all stages of alcohol-related liver disease, including early fibrosis.
The FDA drug label for disulfiram clearly warns that it "should be used with extreme caution in patients with...hepatic cirrhosis or insufficiency" 2. More critically, the FDA label emphasizes that patients should be advised to "immediately notify their physician of any early symptoms of hepatitis" and that "severe and sometimes fatal hepatitis associated with disulfiram therapy may develop even after many months of therapy" 2.
Why This Matters for Early Fibrosis
Even though your patient has only "early" fibrosis, the risks remain substantial:
- Hepatotoxicity can occur regardless of baseline liver function: Recent data from the Drug-Induced Liver Injury Network (DILIN) shows that 71% (5/7) of patients with severe or fatal disulfiram-induced liver injury had underlying liver disease 3
- Disulfiram undergoes hepatic metabolism and can cause liver damage 1
- Fatal outcomes have been reported: Among disulfiram cases in the DILIN study, there were 3 fatal or near-fatal cases (2 liver transplantations and 1 liver-related death) 3
- Timing is unpredictable: Hepatotoxicity typically occurs within 34 days (median) but can develop "even after many months of therapy" 2, 3
Safer Alternatives for Your Patient
First-line recommendation: Acamprosate
- No hepatic metabolism—entirely renally excreted 1
- "The presence of liver disease does not change the indications or conditions of acamprosate use" 4
- No reported instances of hepatotoxicity 1
- FDA-approved for alcohol use disorder
Second-line recommendation: Baclofen
- The only medication studied in RCTs specifically in patients with cirrhosis 1
- "The presence of liver disease does not generally affect the prescribing of baclofen at the doses recommended by the MA (i.e. up to 80 mg/d)" 4
- Use a more gradual dose titration in liver disease 4
- Avoid if hepatic encephalopathy is present 1
Third-line consideration: Naltrexone
- While it undergoes hepatic metabolism and has hepatotoxicity concerns 1, the French guidelines note that "the absolute nature of these contraindications is not supported by solid data" and suggest case-by-case assessment 4
- However, given safer alternatives exist, this should only be considered if acamprosate and baclofen have failed
Critical Caveats
The one observational study suggesting disulfiram might be safe with monitoring 5 is vastly outweighed by:
- Multiple fatal case reports 3, 6
- Explicit guideline contraindications 1
- FDA warnings 2
- The availability of safer, equally effective alternatives
Even with intensive monitoring (liver function tests every 2 weeks for 2 months), fatal hepatotoxicity has occurred 6. The risk-benefit ratio simply does not favor disulfiram use when safer options exist.